EyeGene Balance Sheet Health
Financial Health criteria checks 6/6
EyeGene has a total shareholder equity of ₩64.3B and total debt of ₩2.6B, which brings its debt-to-equity ratio to 4%. Its total assets and total liabilities are ₩78.1B and ₩13.8B respectively.
Key information
4.0%
Debt to equity ratio
₩2.55b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩55.37b |
| Equity | ₩64.33b |
| Total liabilities | ₩13.77b |
| Total assets | ₩78.10b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A185490's short term assets (₩56.9B) exceed its short term liabilities (₩6.1B).
Long Term Liabilities: A185490's short term assets (₩56.9B) exceed its long term liabilities (₩7.7B).
Debt to Equity History and Analysis
Debt Level: A185490 has more cash than its total debt.
Reducing Debt: A185490's debt to equity ratio has reduced from 95% to 4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A185490 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A185490 has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 22.4% each year.